Developing an analytical method by HPLC for simultaneous quantification of methylene blue and metformin applied to in vitro skin permeation and retention studies
- 5 March 2021
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 35 (8) , e5112
Abstract
The aim of this study was to develop an HPLC method for simultaneous quantification of metformin (MET) and methylene blue (MB) in in vitro skin permeation/retention studies, in which retention was evaluated in the different layers of the skin [stratum corneum (SC) and the viable epidermis + dermis (VE + D)]. The method was validated considering the following parameters: specificity, linearity, quantitation limit (LOQ), recovery, precision and accuracy. Calibration curves were obtained using the following six matrices: methanol, water, methanolic extracts from the SC and VE + D spiked with the drugs and drugs extracted from the SC and VE + D. The precision, accuracy and LOQ of the method were evaluated in water and in VE + D and SC, applying the drug extraction process. The results show that the method is selective and linear for both drugs. The precision and accuracy values, independent of matrix and drug, were below the limit of 15%. The LOQ of MB was defined as 0.4 μg/ml in the VE + D and SC and 0.8 μg/ml in water. The LOQ of MET was defined as 0.8 μg/ml in the VE + D and SC and 0.4 μg/ml in the water. The recovery of the method was adequate, consistent and reproducible for the concentration range of 0.4–10 μg/ml for MB (73.3–92.1%) and 0.8–10.0 μg/mL for MET (72.4–94.4%). This method has a potential application in the development of formulation for skin delivery of MB and MET.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/18239‐0)
This publication has 41 references indexed in Scilit:
- Metformin, an Antidiabetic Agent Reduces Growth of Cutaneous Squamous Cell Carcinoma by Targeting mTOR Signaling Pathway†Photochemistry and Photobiology, 2012
- Quantitative Determination of Metformin Hydrochloride in Tablet Formulation Containing Croscarmellose Sodium as Disintegrant by HPLC and UV SpectrophotometryTropical Journal of Pharmaceutical Research, 2012
- Factors influencing tumor response to photodynamic therapy sensitized by intratumor administration of methylene blueLasers in Surgery and Medicine, 2010
- In vivo lymphatic targeting of methylene blue with microemulsion and multiple microemulsionDrug Delivery, 2009
- Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitroEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- New Photodynamic Therapy Protocol to Treat AIDS-Related Kaposi's SarcomaPhotomedicine and Laser Surgery, 2006
- Treatment of melanoma lesions using methylene blue and RL50 light sourcePhotodiagnosis and Photodynamic Therapy, 2004
- Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tabletEuropean Journal of Pharmaceutical Sciences, 2004
- A comparative analysis of phenothiazinium salts for the photosensitisation of murine fibrosarcoma (RIF-1) cells in vitroPhotochemical & Photobiological Sciences, 2004
- Passive skin penetration enhancement and its quantification in vitroEuropean Journal of Pharmaceutics and Biopharmaceutics, 2001